KR20140050661A - 감마-케토알데하이드 소거제로 염증 및 고혈압을 치료하기 위한 방법 - Google Patents

감마-케토알데하이드 소거제로 염증 및 고혈압을 치료하기 위한 방법 Download PDF

Info

Publication number
KR20140050661A
KR20140050661A KR1020147003650A KR20147003650A KR20140050661A KR 20140050661 A KR20140050661 A KR 20140050661A KR 1020147003650 A KR1020147003650 A KR 1020147003650A KR 20147003650 A KR20147003650 A KR 20147003650A KR 20140050661 A KR20140050661 A KR 20140050661A
Authority
KR
South Korea
Prior art keywords
optionally substituted
alkoxy
nitro
alkyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147003650A
Other languages
English (en)
Korean (ko)
Inventor
엘. 잭슨 로버츠
벤카타라만 아마르나쓰
데이비드 쥐. 해리슨
Original Assignee
벤더르빌트 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 벤더르빌트 유니버시티 filed Critical 벤더르빌트 유니버시티
Publication of KR20140050661A publication Critical patent/KR20140050661A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020147003650A 2011-07-12 2012-07-12 감마-케토알데하이드 소거제로 염증 및 고혈압을 치료하기 위한 방법 Ceased KR20140050661A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161506848P 2011-07-12 2011-07-12
US61/506,848 2011-07-12
PCT/US2012/046549 WO2013010034A2 (en) 2011-07-12 2012-07-12 Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197016572A Division KR102050700B1 (ko) 2011-07-12 2012-07-12 감마-케토알데하이드 소거제로 염증 및 고혈압을 치료하기 위한 방법

Publications (1)

Publication Number Publication Date
KR20140050661A true KR20140050661A (ko) 2014-04-29

Family

ID=47506934

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147003650A Ceased KR20140050661A (ko) 2011-07-12 2012-07-12 감마-케토알데하이드 소거제로 염증 및 고혈압을 치료하기 위한 방법
KR1020197016572A Active KR102050700B1 (ko) 2011-07-12 2012-07-12 감마-케토알데하이드 소거제로 염증 및 고혈압을 치료하기 위한 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197016572A Active KR102050700B1 (ko) 2011-07-12 2012-07-12 감마-케토알데하이드 소거제로 염증 및 고혈압을 치료하기 위한 방법

Country Status (13)

Country Link
US (4) US10975033B2 (enExample)
EP (1) EP2731597B1 (enExample)
JP (1) JP6280033B2 (enExample)
KR (2) KR20140050661A (enExample)
CN (2) CN103796648B (enExample)
AU (1) AU2012281061B2 (enExample)
BR (1) BR112014000810A8 (enExample)
CA (1) CA2844150C (enExample)
ES (1) ES2970814T3 (enExample)
HU (1) HUE065757T2 (enExample)
MX (1) MX383365B (enExample)
PL (1) PL2731597T3 (enExample)
WO (1) WO2013010034A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130018478A (ko) * 2011-08-09 2013-02-25 주식회사 엘지화학 신규한 구조의 이차전지 팩
US10166248B1 (en) * 2015-12-21 2019-01-01 Vanderbilt University Methods of preventing platelet activation
US11400103B2 (en) * 2015-12-21 2022-08-02 Vanderbilt University Methods of preventing platelet activation
CA3030036A1 (en) * 2016-07-06 2018-01-11 Vanderbilt University Use of scavengers of reactive gamma-ketoaldehydes to extend cell lifespan and healthspan
PL3481505T3 (pl) * 2016-07-07 2026-01-26 Vanderbilt University Zapobieganie i leczenie migotania/trzepotania przedsionków za pomocą środków wychwytujących gamma-ketoaldehyd
EP3510014B8 (en) * 2016-09-06 2026-07-29 MTI Biotech, Inc. Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nash or ald
PT3512863T (pt) 2016-09-07 2022-03-09 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
EP4385576A3 (en) * 2016-11-15 2024-09-04 Vanderbilt University Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
HUE066390T2 (hu) 2017-04-27 2024-07-28 Univ Vanderbilt Eljárások ateroszklerózis kezelésére gamma-ketoaldehid-szkevendzserekkel
US20210023032A1 (en) 2017-09-05 2021-01-28 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver
WO2019050967A1 (en) * 2017-09-05 2019-03-14 Metabolic Technologies, Inc. COMPOSITIONS AND METHODS OF USING GAMMA-KETOALDEHYDE SENSORS TO TREAT, PREVENT, OR IMPROVE LIVER FIBROSIS
CN109836341B (zh) * 2017-11-28 2021-08-27 江阴技源药业有限公司 一种水杨胺醋酸盐的制备方法
US20200197323A1 (en) * 2018-12-21 2020-06-25 Vanderbilt University Methods for suppressing accumulation of reflux-induced protein adducts
US20230069820A9 (en) * 2019-09-24 2023-03-02 Vanderbilt University Use of 2-hydroxybenzylamine for the treatment of systemic lupus
WO2021154877A1 (en) * 2020-01-27 2021-08-05 Vanderbilt University Mitochondria-targeted isoketal/isolevuglandin scavengers and uses thereof
CN118652245B (zh) * 2024-08-21 2024-11-12 首都医科大学附属北京儿童医院 一种化合物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740439A (en) * 1968-06-24 1973-06-19 Ciba Geigy Corp Treating hypertension with beta-aminoalkane carboxylic acids
US3794734A (en) 1971-03-03 1974-02-26 Merck & Co Inc Methods of treating edema and hypertension using certain 2-aminoethylphenols
US4123537A (en) * 1977-05-26 1978-10-31 Merck & Co., Inc. 2-Halo-4-aminomethyl-6-alkyl-3-pyridinols useful as diuretics in treating hypertension and edema
US8178516B2 (en) * 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
US20050090553A1 (en) * 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
AU5659796A (en) 1995-05-19 1996-11-29 Kissei Pharmaceutical Co. Ltd. 2-hydroxyphenylalkylamine derivatives and maillard reaction inhibitors
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
ATE333868T1 (de) 2000-11-02 2006-08-15 Univ South Carolina Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas
US6824786B2 (en) * 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
US7705054B1 (en) * 2004-10-20 2010-04-27 Vanderbilt University Method of preventing and/or treating oxidant injury in neurodegenerative and oxidative diseases
EP2207555B1 (en) * 2007-10-05 2013-07-24 InDex Pharmaceuticals AB Oligonucleotides for the treatment or alleviation of edema
KR100973343B1 (ko) * 2008-02-01 2010-07-30 롯데칠성음료주식회사 기호성이 우수한 혼합차 조성물 및 그 제조방법
CN101305759B (zh) * 2008-06-19 2011-09-07 成都大学 一种苦荞保健茶及其制备方法
CN101843671A (zh) * 2009-03-25 2010-09-29 王文祥 苦荞托毒丸及其制备方法
EP2477594A4 (en) * 2009-07-15 2013-03-13 Univ Vanderbilt ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY
CN101606986A (zh) * 2009-07-29 2009-12-23 李钢 一种具有降糖作用的组合物及其药物

Also Published As

Publication number Publication date
CA2844150C (en) 2019-09-03
BR112014000810A2 (pt) 2017-06-13
JP2014524918A (ja) 2014-09-25
MX383365B (es) 2025-03-13
EP2731597A2 (en) 2014-05-21
US10975033B2 (en) 2021-04-13
AU2012281061A1 (en) 2014-02-20
PL2731597T3 (pl) 2024-04-29
MX2014000515A (es) 2014-03-27
US20250034093A1 (en) 2025-01-30
ES2970814T3 (es) 2024-05-30
US20140256774A1 (en) 2014-09-11
AU2012281061B2 (en) 2017-08-03
CN103796648B (zh) 2019-10-25
KR102050700B1 (ko) 2019-11-29
CN103796648A (zh) 2014-05-14
WO2013010034A3 (en) 2013-03-28
HUE065757T2 (hu) 2024-06-28
BR112014000810A8 (pt) 2022-11-29
WO2013010034A2 (en) 2013-01-17
EP2731597B1 (en) 2023-12-20
CA2844150A1 (en) 2013-01-17
KR20190069607A (ko) 2019-06-19
JP6280033B2 (ja) 2018-02-14
CN111494352A (zh) 2020-08-07
EP2731597C0 (en) 2023-12-20
US20250214939A1 (en) 2025-07-03
EP2731597A4 (en) 2015-04-08
US20210261508A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
KR20190069607A (ko) 감마-케토알데하이드 소거제로 염증 및 고혈압을 치료하기 위한 방법
KR102497487B1 (ko) 피페리디닐-인돌 유도체의 신규 용도
US20090227602A1 (en) Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
JP2009521408A (ja) Ｃｄｃ２様キナーゼ（ＣＬＫ）のモジュレータおよびその使用方法
KR20010034861A (ko) 항박테리아제로서의 히드록삼산 유도체
CN106456606A (zh) 吲哚基及吲哚啉基异羟肟酸于治疗神经退化病症或认知缺乏的用途
WO2012171974A1 (en) Tadalafil for the treatment of dementia
KR20140105598A (ko) [1,2,4]트리아졸로피리딘 및 포스포디에스테라제 억제제로서의 이의 용도
JP5788907B2 (ja) 疾患の治療に使用される化合物
US20130274212A1 (en) Sesterterpene Compounds and Use Thereof
CA3022013C (en) Secreted pla2 inhibitors for immediate treatment of hymenoptera envenomation
US20230355549A1 (en) Method of preventing kidney injury disruption of intestinal lymphatics
WO2021177332A1 (ja) Ｎｌｒｐ３インフラマソーム阻害剤及び炎症性疾患の予防又は治療のための医薬組成物
HK40023703A (en) Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
JP2022506548A (ja) 化合物の抗ｐｃｓｋ９（抗プロタンパク質変換酵素スブチリシン ケキシン９型）ナノ製剤および心血管疾患の治療および／または予防におけるその使用方法
WO2011151330A1 (en) 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the therapy of prion diseases
US20020068722A1 (en) Alpha-substituted thio,-oxo trifluoromethylketones as phospholipase inhibitors
JP2006282639A (ja) プロスタグランジン産生阻害剤及び抗炎症剤
WO2025221864A1 (en) Compositions and methods for restoring cognitive and behavioral function
WO2025221944A1 (en) Compositions and methods for treating joint and bone diseases
US20210000841A1 (en) Compounds that modulate von willebrand factor levels and their use in the treatment of blood disorders
KR20220165520A (ko) 헵시딘 억제제를 포함하는 노인성 뇌질환의 예방, 개선, 및/또는 치료용 조성물
HK1191859A (en) Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
WO2015027040A2 (en) Methods and compositions for treating schistosome infection

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140212

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170711

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180809

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190123

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180809

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190123

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20181008

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20170711

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20140303

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20190508

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190424

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20190123

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20181008

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180809

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170711

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20140303

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190610